EI
KYMR icon

EAM Investors’s Kymera Therapeutics KYMR Stock Holding History

EAM Investors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.41M Sell
21,056
-21,285
-50% -$1.83M 0.22% 167
2026
Q1 		$3.53M Sell
42,341
-14,114
-25% -$1.12M 0.41% 117
2025
Q4 		$4.39M Sell
56,455
-1,130
-2% -$76.3K 0.49% 100
2025
Q3 		$3.21M Buy
+57,585
New +$2.6M 0.37% 135

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

EAM Investors's KYMR Position: Q2 2026 in Review

EAM Investors reduced its Kymera Therapeutics (KYMR) stake by 50% in Q2 2026, selling an estimated $1.83M and leaving 21,056 shares worth $2.41M. The position accounts for 0.22% of the portfolio, ranked #167.

EAM Investors first reported a position in KYMR in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.39M in Q4 2025. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • EAM Investors held 21,056 shares of Kymera Therapeutics worth $2.41M as of Q2 2026.
  • EAM Investors sold 21,285 Kymera Therapeutics shares in Q2 2026, an estimated $1.83M.
  • Kymera Therapeutics made up 0.22% of EAM Investors's portfolio in Q2 2026, its #167 holding.
  • EAM Investors first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • EAM Investors's Kymera Therapeutics position peaked at $4.39M in Q4 2025.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.